Virus inhibition activity of effector memory CD8+ T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection by Yamamoto, Takuya et al.
  Published Ahead of Print 14 March 2012. 
2012, 86(10):5877. DOI: 10.1128/JVI.00315-12. J. Virol. 
Daniel C. Douek and Richard A. Koup
Lefebvre, Gary J. Nabel, Elias K. Haddad, Norman L. Letvin,
Roederer, Srinivas S. Rao, Adrian B. McDermott, Francois 
Petrovas, Martha Nason, Wendy W. Yeh, Ling Shen, Mario
David I. Wolinsky, Jorge R. Almeida, Constantinos 
Takuya Yamamoto, Matthew J. Johnson, David A. Price,
 
Breakthrough Infection
Vaccinated Monkeys after Vaccine
Immunodeficiency Virus Load in 
 T Cells Determines Simian+CD8
Virus Inhibition Activity of Effector Memory
http://jvi.asm.org/content/86/10/5877
Updated information and services can be found at: 
These include:
SUPPLEMENTAL MATERIAL
 Supplemental material
REFERENCES
http://jvi.asm.org/content/86/10/5877#ref-list-1at: 
This article cites 29 articles, 16 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
Virus Inhibition Activity of Effector Memory CD8 T Cells
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Martha Nason,c Wendy W. Yeh,d Ling Shen,d Mario Roederer,a Srinivas S. Rao,a Adrian B. McDermott,a Francois Lefebvre,e
Gary J. Nabel,a Elias K. Haddad,e Norman L. Letvin,d Daniel C. Douek,a and Richard A. Koupa
Vaccine Research Centera and Biostatistics Research Branch,c NIAID, NIH, Bethesda, Maryland, USA; Department of Infection, Immunity and Biochemistry, Cardiff University
School of Medicine, Cardiff, Wales, United Kingdomb; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USAd; and VGTI-FL, Port St.
Lucie, Florida, USAe
The goal of an effective AIDS vaccine is to generate immunity that will prevent human immunodeficiency virus 1 (HIV-1) acqui-
sition. Despite limited progress toward this goal, renewed optimism has followed the recent success of the RV144 vaccine trial in
Thailand. However, the lack of complete protection in this trial suggests that breakthroughs, where infection occurs despite ade-
quate vaccination, will be a reality for many vaccine candidates. We previously reported that neutralizing antibodies elicited by
DNA prime-recombinant adenovirus serotype 5 (rAd5) boost vaccination with simian immunodeficiency virus strain mac239
(SIVmac239) Gag-Pol and Env provided protection against pathogenic SIVsmE660 acquisition after repeated mucosal challenge.
Here, we report that SIV-specific CD8 T cells elicited by that vaccine lowered both peak and set-point viral loads in macaques
that became infected despite vaccination. These SIV-specific CD8 T cells showed strong virus-inhibitory activity (VIA) and dis-
played an effector memory (EM) phenotype. VIA correlated with high levels of CD107a mobilization and perforin expression in
SIV-specific CD8 T cells. Remarkably, both the frequency and the number of Gag CM9-specific public clonotypes were strongly
correlated with VIAmediated by EMCD8 T cells. The ability to elicit such virus-specific EMCD8 T cells might contribute
substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection.
Multiple lines of evidence indicate that virus-specific CD8 Tcells are responsible for the immediate and long-term con-
trol of human immunodeficiency virus (HIV) and simian immu-
nodeficiency virus (SIV) replication in vivo (5, 10, 17, 28). Thus,
the ability to elicit a durable and potent HIV-1-specific CD8 T
cell response following vaccination will remain an important
characteristic of vaccines that do not achieve full sterilizing immu-
nity in all vaccinees. The measurement of virus inhibition ex vivo
and in vitro, using infected primary autologous CD4 T cells as
targets, encompasses the totality of the potential inhibitorymech-
anisms deployed by CD8 T cells (7). Therefore, the virus inhibi-
tion assay measures the overall potency of the CD8 T cell-medi-
ated antiviral response elicited by infection or vaccination.
A public clonotype specific for a particular epitope is defined as
a T cell receptor beta (TCRB) amino acid sequence that occurs in
more than one individual (32). Previous work has shown that
CM9-specific public clonotype usage predicts the set-point viral
load (VL) that emerges during early-chronic-phase infection (22,
32). Despite significant work to clarify the mechanism underlying
the generation of public clonotypes and the viral control offered
by them (2, 6, 21, 23, 30, 31), our understanding of how they
mediate protection is far from complete. Thus, a comprehensive
understanding of the TCR traits that can predict immune re-
sponses and viral outcomes is warranted in future efficacious vac-
cine trials.
We have shown previously that immunization with a DNA
prime-recombinant adenovirus serotype 5 (rAd5) boost vaccine
comprising SIVmac239 Gag-Pol and Env protected Mamu-
A*01 rhesus macaques against SIVsmE660 infection (19). The
protection was incomplete but correlated with the induction of
SIV-specific neutralizing antibodies. In addition, macaques ex-
pressing two TRIM5 alleles that restrict SIV replication weremore
likely to be protected from infection than macaques expressing at
least one permissive TRIM5 allele. Here, we determined whether
this vaccine also had an impact on virologic control in those ma-
caques that became infected despite vaccination. Our results show
that vaccine-induced SIV-specific effectormemory (EM)CD8T
cells that display strong virus-inhibitory activity (VIA) and incor-
porate public TCRs are associated with SIV control in macaques
with breakthrough infection.
MATERIALS AND METHODS
Animals. Adult rhesus monkeys of Indian origin were used in the study
after full protocol approvals from the Institutional Animal Care and Use
Committees of the Vaccine Research Center, NIAID, NIH, and Bioqual,
Inc., where the animals were housed. Both institutions are fully accredited
by the Association for Accreditation of Laboratory Animal Care, Interna-
tional (AAALAC,I). All experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals (20) and all insti-
tutional, state, and federal guidelines.
Rhesus monkeys were immunized with plasmid DNA (4 mg per con-
struct, intramuscularly, at weeks 0, 4, and 8) and rAd5 vectors (1 1011
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particles per construct, intramuscularly, at week 26) using vectors ex-
pressing SIVmac239 Gag-Pol and Env.
Viral load quantification. Plasma SIV RNA was determined for all
SIVsmE660 studies using previously published protocols (19).
Antibodies.The following directly conjugatedmonoclonal antibodies
(MAbs) were used: CD3-Cy7APC, CD107a-FITC, IL-2-Cy5.5PerCP,
MIP-1-PE, IFN--V450, and CD95-Cy7PE (BD Biosciences), CD28-
TexasRedPE (Beckman Coulter), granzyme-B-Cy5.5PE, CD4-Qdot605,
and CD8-Qdot655 (Invitrogen), PD-1-Cy5.5PerCP and granzyme-A-pa-
cific blue (Biolegend), and perforin-FITC (Mabtech). Aqua amine reac-
tive viability dyes were obtained from Invitrogen.
Polychromatic flow cytometry. Cells were analyzed using a modified
LSR II flow cytometer (BD Immunocytometry Systems) as described previ-
ously (18). Briefly, 2  106 peripheral blood mononuclear cells (PBMCs)
were incubated in 1ml of RPMI 1640medium supplemented with 10% fetal
bovine serum (FBS) and penicillin/streptomycin that contained monensin
(0.7 g/ml; BD Biosciences) and brefeldin A (10 g/ml; Sigma-Aldrich) in
the absence or presence of CD107aMAbs and peptides (15mers overlapping
by 11 residues) corresponding to full-length SIVmac239 Gag (2 g/ml for
each peptide at 5 l/ml; National Institutes of Health AIDS Research and
ReferenceReagent Program) for 6 h. Afterwashing, cells were surface stained
forCD4,CD8,CD28, andCD95; aquaamine reactivedyewasused toexclude
dead cells from the analysis. Following permeabilization (Cytofix/Cytoperm
kit; BD Biosciences), cells were stained for CD3, gamma interferon (IFN-),
interleukin 2 (IL-2), MIP-1, and tumor necrosis factor alpha (TNF-). Be-
tween 3  105 and 1  106 events were collected in each case. Electronic
compensation was conducted with MAb capture beads (BD Biosciences)
stained separately with the individual MAbs used in the test samples. Data
were analyzed using FlowJo version 9.3.3 (TreeStar). Forward scatter area
versus forward scatter height was used to gate out cell aggregates. CD14,
CD19, anddeadcellswere removed fromthe analysis to reducebackground
staining.
Peptide-major histocompatibility complex (MHC) class I tetram-
ers. Soluble fluorochrome-labeled peptide-Mamu-A*01 (pMamu-A*01)
SIV Gag CM9-specific tetramers were produced and used as described
previously (22, 23) (CM9; CTPYDINQM, residues 181 to 189). For phe-
notypic analyses of pMamu-A*01–allophycocyanin (APC) tetramer-la-
beled cells, between 3 105 and 1 106 events were acquired on an LSR
II flow cytometer (BD). The following reagents andMAb specificitieswere
used: aqua, CD3, CD4, CD8, CD28, CD95, PD-1, perforin, granzyme A,
and granzyme B.
Virus inhibition assay.Virus-inhibitory activity (VIA) was measured
as follows. PBMCs from each macaque were thawed in RPMI 1640 sup-
plemented with 10% FBS and penicillin/streptomycin and stimulated
with concanavalin A (25 g/ml) in the presence of recombinant human
interleukin-2 (rhIL-2) at a concentration of 50 U/ml (PeproTech). After
stimulation for 1 day, the medium was replenished and the cells were
incubated for an additional day. PBMC targets were depleted of CD8
cells using a magnetically activated cell sorting (MACS) nonhuman pri-
mate CD8MicroBead kit (Miltenyi Biotec) according to the manufactur-
er’s instructions. Effectormemory (EM)CD8T cells were sorted by flow
cytometry using the fluorescence-activated cell sorter (FACS) Aria (BD)
based on the differential expression of CD28 and CD95. Target PBMCs
were infected at 1 106 cells/ml using amultiplicity of infection (MOI) of
0.004 to 0.06 by spinoculation at 1,200 g for 2 h. Following spinocula-
tion, cells were resuspended and plated at 4  104 cells per well in a
flat-bottom 96-well tissue culture plate. EM CD8 T cells were serially
diluted 2-fold from 2 105 to 4 104 cells/ml and added to autologous
infected targets at corresponding effector/target (E:T) ratios of 5:1, 2:1,
and 1:1. Infectivity controls consisted of infected targets without added
CD8 effectors. Cultures were incubated at 37°C and 5% CO2 for 3 or 5
days. Viral replication wasmeasured by the SIV p27 antigen capture assay
(Advanced BioScience Laboratories Inc.). Viral inhibition was calculated
as a percentage of the infectivity control for each E:T ratio and a log
reduction of SIV p27 levels compared to that of infectivity controls at an
E:T ratio of 5:1.
Clonotype analysis. Viable tetramer-stained central memory (CM),
EM, and total CD8T cells were sorted by flow cytometry at98%purity
into 1.5-ml microtubes containing 150 l RNAlater. The number of
sorted cells for each CM9-specific population ranged from 470 to 5,000
cells. mRNA was extracted using the MACSmRNA isolation kit (Milte-
nyi Biotec). Unbiased amplification of all expressed TRB gene products
was achieved using a template switch-anchored reverse transcriptase
(RT)-PCR (25). Amplicons were subcloned and sequenced as described
previously (6, 25). Sequence reads were analyzed to determine T cell re-
ceptor beta variable (TRBV) and T cell receptor beta joining (TRBJ) gene
usage, CDR3 sequences, and CDR3 length.
Microarray and pathway analysis. Gag CM9-specific EM CD8 T
cells (CD28lowCD95high tetramer) from SIV-negative macaques at 12
weeks post-DNA/rAd5 immunization were sorted by flow cytometry as
described above for microarray studies. Eleven RNA samples from two
groups based on the VIA data (CM9 peptide-stimulated cells from ma-
caques with strong VIA or those with weak VIA) and two groups based
on cell treatment (cells from macaques with strong VIA with or with-
out CM9 peptide stimulation) were prepared using the Illumina beads
station assay as described previously (8, 24) and hybridized to the
Illumina HumanHT-12 version 4 Expression BeadChip according to
themanufacturer’s instructions. Analysis of the GenomeStudio output
data was conducted using the R statistical language (27) and various
software packages from Bioconductor (9). Quantile normalization was
applied, followed by a log2 transformation. The LIMMA package (29)
was used to fit a single linear model to each probe and to perform
(moderated) t tests on the differences of interest. Two differences were
tested, the first between CM9 peptide-stimulated and nonstimulated
CM9 EM CD8 T cells from macaques with strong VIA and the
second between CM9 peptide-stimulated CM9 EM CD8 T cells
from monkeys with strong VIA and those from monkeys with weak
VIA. The expected proportions of false positives (false discovery rate
[FDR]) were estimated from the unadjusted P values using the Benja-
mini and Hochberg method. Pathway, functional, and network anal-
ysis were conducted with ingenuity pathway analysis (IPA; Ingenuity
Systems, Redwood City, CA). The input data include genes whose
expression levels met the following criteria: fold change of1.5 (up or
down) and raw P value of0.01. The genes in the data were mapped to
the ingenuity pathway knowledge base with different colors (red, up-
regulated; green, downregulated), and the networks for immunologi-
cal disease, inflammatory disease, and neurological disease were fur-
ther explored.
TRIM5 genotyping. Genomic DNA was isolated from lymphocytes
using the QIAamp DNA kit (Qiagen) and sequenced for TRIM5 exons as
described previously (19).
Statistical analysis. Experimental variables were analyzed using the
nonparametric Mann-Whitney U test and the Wilcoxon matched-pairs
signed-rank test. Correlations were performed using the nonparametric
Spearman rank test. Bars depict median values; P values of 0.05 were
considered significant. The GraphPad Prism statistical analysis program
(GraphPad Software) was used throughout. Analysis and graphical repre-
sentation of cytokine production were conducted using the data analysis
program Simplified Presentation of Incredibly Complex Evaluations
(SPICE; version 5.2), provided by M. Roederer, National Institutes of
Health, Bethesda, MD.
Microarray data accession number.All data were deposited in a pub-
lic repository, the National Center for Biotechnology Information Gene
ExpressionOmnibus (GEO), and can be accessed at http://www.ncbi.nlm
.nih.gov/geo (accession no. GSE35628).
RESULTS
The DNA prime-rAd5 boost elicits CD8 T cell-mediated virus
inhibition. Thirty-nine Mamu-A*01 rhesus monkeys were given
Yamamoto et al.
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the DNA prime-rAd5 boost vaccine encoding either SIVmac239
Gag-Pol and Env or a placebo and were subsequently challenged
by repeated rectal inoculation with SIVsmE660. While protection
was afforded by the vaccine, seven vaccinated monkeys became
infected (19) (see Fig. S1A in the supplemental material).
No VIA was detected in naive CD8 T cells at week 4 and week
16 post-rAd5 boost in either control or vaccinated monkeys (Fig.
1A, upper). However, at week 4 postboost, VIA was detected in
both central memory (CM) and effector memory (EM) CD8 T
cells within the vaccinated monkeys (Fig. 1A, lower) (CM, P 	
0.0013; EM, P  0.0001). VIA persisted through week 16 post-
boost (CM, P 	 0.0007; EM, P 	 0.0222) and was not related to
the number of TRIM5 alleles that restrict SIV replication (see Fig.
S1B in the supplemental material).
We compared VIAs in vaccinated macaques by whether or not
theybecame infected after repeated rectal challengewithSIVsmE660.
No differences in VIA were apparent between the two groups (Fig.
1B) (P	 0.7577). These data agreewith a prior report which showed
no association between either CD8 T cells or innate immune re-
sponses and protection against virus acquisition (19). However,
among the macaques that became infected, those with more than 1
log of vaccine-inducedVIA (strongVIA)within the EMCD8T cell
compartment showed lower plasma VLs than those with less than 1
logofVIA (weakVIA) (Fig. 1C).Wedidnot observe any relationship
between VIAwithin CMCD8 T cells and VL at any time point (see
Fig. S1C in the supplemental material).
There was an inverse correlation between set-point VL and
prechallenge VIA within EM CD8 T cells (Fig. 1D) (P 	 0.007,
FIG 1 Relationship between VIA and control of SIV replication. (A) The upper panels show the VIA of naïve CD8 T cells against SIVsmE660 for 10 control
macaques and 13 vaccinated macaques at week 4 (WK4) after the rAd5 boost and for 7 control macaques and 13 vaccinated macaques at week 16 (WK16) after
the rAd5 boost. The lower panels show pooled data for the log reduction of SIV replication at week 4 after the rAd5 boost (CM, n	 13; EM, n	 16) and at week
16 after the rAd5 boost (CM, n 	 14; EM, n 	 16). The inhibition is calculated as the log10 reduction in virus infection, measured by an SIV Gag p27
enzyme-linked immunosorbent assay (ELISA), compared to that of the autologous infectivity controls. The dotted line shows no reduction. P values were
calculated using the Mann-Whitney U test. (B) Pooled data of VIA against SIVsmE660 in vaccinated macaques, comparing infection outcomes after repeated
mucosal challenge. A threshold for positive antiviral activity was established at 3 standard deviations above a 1-log reduction. Red dots represent infected
macaques that exhibited less than 1 log of VIA. (C) Longitudinal VLmeasurements are shown for each macaque over an 18-week period from time of infection.
Red lines represent macaques that displayed less than 1 log of VIA (weak VIA). Black lines represent the macaques that displayedmore than 1 log of VIA (strong
VIA). (D) Simple linear regressions predicting mean set-point log10 VLs fromweeks 6 to 9 after infection by VIA within the EMCD8
 T cell population at week
16 after the rAd5 boost (n	 7). (E) Simple linear regressions predicting mean peak log10 VLs by VIA within the EMCD8
 T cell population at week 16 after the
rAd5 boost (n	 7).
VIA of EM CD8 T Cells in Vaccinated Monkeys
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FIG 2 CM9-specific EM CD8 T cells with strong VIA exhibit a transcriptional profile distinct from that of cells with weak VIA. (A) Heat map representation
of the expression values for the top 50 (FDR estimated at 0.09%) genes that are most significantly differentially expressed between nonstimulated CM9-specific
EM CD8 T cells (n	 6) and stimulated CM9-specific EM CD8 T cells (n	 3). Rows represent genes, and columns represent samples. Colors correspond to
the value of the within-gene (row) standard score. (B) Relative (stim versus nonstim) expression levels of stimulated CM9-specific EM CD8 T cells for a
selection of 11 functionally relevant genes. All genesmeet the requirement of aP value of0.005 and are found at a 5%FDRexcept for FASLG (9%),CCL1 (17%),
and CCL5 (22%). Panels C and D are the same as panels A and B except that they show the comparison between stimulated CM9-specific EMCD8 T cells with
strong VIA (n	 2) and stimulated CM9-specific EM CD8 T cells with weak VIA (n	 3). The FDR in panel C is estimated at 0.3%. Selected genes in panel D
meet the requirement of a P value of0.003 and are found at 5% FDR except for TNFSF14 (7%), TNFSF9 (10%), and TNF (12%).
Yamamoto et al.
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r 	 
0.89). This inverse correlation was also observed between
peak VL and prechallenge VIA within EM CD8 T cells (Fig. 1E).
Neither the peak nor set-point VL was related to the frequency of
CM9-specific CD8 T cells in either the EM or total CD8 T cells
(see Fig. S2A toD in the supplementalmaterial). In addition, there
was no relationship between the VIA of EM CD8 T cells and the
frequency of CM9-specific CD8 T cells in either the EM or total
CD8 T cell compartments (see Fig. S2E and F in the supplemen-
tal material).
Molecular gene signature of Gag CM9-specific EM CD8 T
cells.Microarray gene analysis was performed on immunodomi-
nant CM9-specific EM CD8 T cells. CM9-specific EM CD8 T
cells from macaques with strong VIA were sorted by flow cytom-
etry with (stim) or without (nonstim) prior CM9 peptide stimu-
lation. (stim, n	 3; nonstim, n	 6). A heatmap representation of
the 50 genesmost significantly upregulated after CM9 stimulation
is shown in Fig. 2A, while Table S1 in the supplemental material
provides the full list of 677 upregulated genes. A selection of genes
known to be upregulated with TCR stimulation and related to the
functional activities of CD8 T cells is shown in Fig. 2B. We ob-
served significant increases in the expression of genes encoding
cytokines (TNF, IL-2), chemokines (CCL1, CCL3, CCL5, and
CCL3L1), transcription/activation markers (CD69, NFATC1),
and cytolytic molecules that are related to the killing activity of
FIG 3 Functional profiles of SIV-specific CD8 T cell responses. (A to D) Flow cytometric analysis of CD107a mobilization and the production of IFN-, IL-2,
MIP-1, TNF, granzymeA, granzymeB, andperforinwithinGag-specificCD8T cells. (A andC)The proportions of the totalGag-specificCD8T cell response
contributed by each function inmacaques with strong VIA (n	 6; open) andweak VIA (n	 5; red) are shown, with boxes representing interquartile ranges. The
magnitude of the Gag-specific response in total EM CD8 T cells (A) or the CM9-specific response in CM9-specific EM CD8 T cells (C) was calculated based
on the summation of all individual functional response patterns. Horizontal bars represent median values. (B) The pie charts show the fractions of cells with 1,
2, 3, 4, and 5 functions. The color-coded circles indicate the proportions of the 5, 4, 3, 2, and 1 functional responses that are contributed by the single cytokines
CD107a (red), IFN-, (yellow), IL-2 (green), MIP-1 (blue), and TNF (purple). (D) The pie charts show the fractions of cells with 1, 2, and 3 functions. The
color-coded circles indicate the proportions of the 3, 2, and 1 functional responses that are contributed by the single cytolytic enzymes granzyme A (red),
granzyme B (green), and perforin (blue). (E) Simple linear regressions predicting the percentage of CD107a Gag-specific EM CD8 T cells (left) and the
percentage of perforin-positive (perforin) CM9-specific EMCD8T cells (right) by VIAwithin the EMCD8T cell population at week 16 after the rAd5 boost
(n	 11).
VIA of EM CD8 T Cells in Vaccinated Monkeys
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CD8 T cells (FASLG, 4-1BB, and HVEML) in stimulated cells
compared to that in nonstimulated cells.
We then compared the gene profiles of CM9-stimulated EM
CD8 T cells from monkeys with strong VIA and those from
monkeys with weak VIA (n 	 3 and 2, respectively). Stimulated
CM9-specific EM CD8 T cells from monkeys with strong VIA
were transcriptionally distinct from those from monkeys with
weak VIA (Fig. 2C; see also Table S2 in the supplemental mate-
rial). Single-gene analysis (Fig. 2D) revealed the increased expres-
sion of cytokines (TNF and IL-2), chemokines (CCL5 and
CCL3L1), a transcription/activation marker (CD69), and cyto-
lytic molecules related to the killing activity of CD8 T cells
(FASLG, PRF1, GrzA, GrzK, 4-1BB, and HVEML) in monkeys
with strong VIA compared to that in monkeys with weak VIA. Of
note, the increased expression of PRF1, GrzA, and GrzK was ap-
parent only in the comparison between strong and weak VIAs,
indicating that the amount of endogenous expression of these
genes was higher for strong than for weak VIA. We also identified
several canonical pathways that were differentially regulated in
peptide-stimulatedCM9-specific EMCD8T cells when compar-
ing monkeys with strong VIA and those with weak VIA (see Fig.
S3A in the supplemental material). Furthermore, biological func-
tions related to protein synthesis, RNA posttranscriptional mod-
ification, gene expression, cell death, and cellular development
were also profoundly different (see Fig. S3B in the supplemental
material). The canonical pathway of apoptosis signaling was also
found to be significant (see Fig. S3C in the supplemental mate-
rial). Caspase8/10 and caspase2 were decreased and Bfl-1 was up-
regulated in association with strong VIA compared to levels with
weak VIA. These data suggest an enhanced antiapoptotic status of
CM9-specific EM CD8 T cells for strong VIA compared to that
for weak VIA.
Functional profiles of Gag CM9-specific EM CD8 T cells.
We next assessed the functions of vaccine-induced CM9-specific
EM CD8 T cells by polychromatic flow cytometry. Macaques
with strong VIA mobilized higher levels of CD107a than ma-
caques with weak VIA, although this comparison was not statisti-
cally significant (Fig. 3A) (P	 0.0823). This difference wasmostly
due to an increase in single-positive CD107a cells in macaques
with strong VIA, although a slight increase in the fraction of mul-
tifunctional cells was observed as well (Fig. 3B). No differences
were observedwith respect to the production of IL-2, IFN-,MIP-
1, or TNF between these two groups.
Perforin expression in CM9-specific EMCD8 T cells trended
toward higher levels in the strong VIA group (P 	 0.0823). The
strong and weak VIA groups exhibited similar levels of granzyme
A and granzyme B expression (Fig. 3 C). There were no significant
differences in the simultaneous expression of killing molecules
between the strong and weak VIA groups (Fig. 3D), although the
increase in perforin staining resulted in an increase in the fractions
of both multifunctional and single perforin-positive cells in the
strong VIA group. The VIA of EM CD8 T cells was positively
associated with both CD107a mobilization and perforin expres-
sion in EM CD8 T cells (CD107a, P 	 0.0074, r 	 0.7727; per-
forin, P	 0.0336, r	 0.6545) (Fig. 3E).
Public clonotype usage in Gag CM9-specific EM CD8 T cell
populations predicts VIA. Next we sorted the CM9-specific
CD8 T cell populations and sequenced the constituent TCRB
chains (25). More CM9-specific public clonotypes were observed
in macaques with strong VIA than in monkeys with weak VIA
(Fig. 4A).Macaques with weak VIA possessed fewer, if any, public
clonotypes within CM9-specific CD8 T cells (Fig. 4B). Although
the mechanism for this predictive association is largely unknown,
it has been suggested that certain public clonotypes suppress viral
replication more effectively (16). Accordingly, we measured the
number and frequency of public clonotypes in each SIV-infected
macaque and compared these parameters with the VIA. Signifi-
cant positive correlations were detected between the in vitro log
reduction of SIV and both the number and frequency of public
clonotypes within the CM9-specific EM CD8 T cell compart-
ment (Fig. 4C). No such relationship was found in the CM CD8
T cell compartment (Fig. 4D).
DISCUSSION
Here we show that vaccine-induced VIA in EM CD8 T cells
predicts better viral control in monkeys that are not protected
against infection with SIVsmE660. This VIA is associated with
increased expression of genes regulating cytokine, chemokine,
and cytolytic molecules, functional evidence of greater degranu-
lation, and more perforin production within the EM CD8 T cell
response. Earlier work has also shown that HIV-specific CD8 T
cells from elite controllers have higher perforin content and
CD107a mobilization than chronically infected progressors (7, 13,
14). Evenwithin theMamu-A*01macaques,weobserved that these
two factors correlatedwith theVIAofEMCD8Tcells.Onthisbasis,
we propose that it is relevant and direct to assess the function of EM
CD8 T cells by VIA when evaluating HIV/AIDS vaccines.
Effector memory SIV-specific CD8 T cells targeting epitopes
other than Gag CM9 contribute to the overall T cell response to
SIV, and it is unclearwhether our results, both in terms ofVIA and
public clonotypes, extend beyond this single epitope. However,
our data do extend prior findings by demonstrating that public
clonotype usage within protective Gag CM9-specific EM CD8 T
cells is associated with in vitro virus inhibition. Previous work has
shown that CM9-specific public clonotype usage during acute in-
fection or after vaccination predicts the set-point VL that emerges
during early-chronic-phase infection (22). However, the mecha-
nism underlying this observation remains enigmatic. In broad
terms, it has been postulated that two nonmutually exclusive ef-
fects may be at play. First, CM9-specific public clonotypes might
be mobilized with more-rapid kinetics as a function of higher
precursor frequencies in the naïve pool generated by the process of
convergent recombination (26, 32, 33), with attendant mitigation
of the mucosal immune damage that occurs during the acute
FIG 4 Clonotypic architecture of Gag CM9-specific CD8 T cells. (A and B) TRBV and TRBJ usage, CDR3 amino acid sequences, and the relative frequencies
of CD8 T cell clonotypes specific for the CM9 epitope are shown for 5 macaques with strong VIA (A) and 6 macaques with weak VIA (B) at week 12 after the
rAd5 boost. Colored boxes indicate public clonotypes. Public clonotypes were defined on the basis of TRB amino acid sequences that were present in more than
one macaque, with reference to the present data and previously published sequences (15, 22, 23). (C) Simple linear regressions predicting the VIA of EM CD8
T cells from week 12 after the rAd5 boost by the number of public clonotypes (left) and the frequency of public clonotypes (right) present in the CM9-specific
CD8 T cell population (n	 11). (D) Simple linear regressions predicting the VIA of CM CD8 T cells from week 12 after the rAd5 boost by the frequency of
public clonotypes (left) and the number of public clonotypes (right) present in the CM9-specific CD8 T cell population (n	 11).
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phase of infection leading to improved outcomes (4). Second,
intrinsic properties of public clonotypes per se might explain the
observed biological effects (3, 16). Indeed, it seems that public
clonotypes, at least in the setting of CM9-specific CD8 T cell
populations, are more cross-reactive and, hence, better able to
recognize viral variants (22). Nevertheless, it remains unclear
whether this is a determinative effect or an epiphenomenon.Here,
we show that CM9-specific public clonotypes confer enhanced
VIA within the EM CD8 T cell compartment, a parameter that
was not directly assessed in previous studies. Thus, these data de-
fine a potential mechanistic basis for the observed protective ef-
fects of public clonotypes in this setting and emphasize the poten-
tial importance of TCR repertoire analyses as a component of
immune monitoring in HIV/SIV vaccine trials (1).
It has been reported that antigen-specific EM CD8 T cells
elicited by vaccination with rhesus cytomegalovirus (RhCMV)
vectors can profoundly control SIV after intrarectal SIV challenge
in some macaques (11, 12). Using these vectors, high frequencies
of SIV-specific EM CD8 T cells are elicited at potential sites of
virus replication in rhesus macaques that stringently control
highly pathogenic SIVmac239 infection early after mucosal chal-
lenge. Our results support the role of EM CD8 T cells in the
control of HIV/SIV infection, although antigen-specific CD8 T
cells elicited by DNA-rAd5 vaccination were unable to exert the
profound control observed after RhCMV/SIV vaccination. The plas-
mid DNA prime-rAd5 boost vaccine used in this study was strongly
immunogenic (11) and induced both CD8 T cell responses and
Env-specific antibody responses. Indeed, both neutralizing antibod-
ies (which were associated with protection against acquisition) and
EMCD8 T cells with strong VIA (which were associated with viro-
logic control after infection) were induced. This vaccine approach
offers the potential to decrease the incidence ofHIV acquisition after
sexual exposure and enhance immune control of viral replication
even after vaccine breakthrough infection.
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